• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Privia Health Announces Appointment of Lance V. Berberian to its Board of Directors

    7/8/25 9:00:00 AM ET
    $LH
    $PRVA
    Medical Specialities
    Health Care
    Medical/Nursing Services
    Health Care
    Get the next $LH alert in real time by email

    ARLINGTON, Va., July 08, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (NASDAQ:PRVA) announced the appointment of Lance V. Berberian to its Board of Directors, effective July 15, 2025. He has also been named a member of the Audit Committee of the Board. Following the appointment of Mr. Berberian, the Board will comprise 10 directors.

    "We are excited to welcome Lance to our Board of Directors," said David King, Chairman of the Board, Privia Health Group, Inc. "Lance brings extensive technology strategy and digital transformation experience to the Board, including IT governance, infrastructure management and cybersecurity. We believe his expertise will be invaluable to Privia Health as we continue to grow our business and build scaled provider networks across the U.S."

    Mr. Berberian is a technology strategist with over 30 years of experience specializing in digital transformation and corporate governance. From 2014 to October 2024, he served as EVP and Chief Information and Technology Officer at Labcorp Holdings Inc. (NYSE:LH), overseeing a team of 5,000 people focused on IT strategy, cybersecurity, AI, product development, and data management. Prior to Labcorp, Mr. Berberian held CIO roles at IDEXX Laboratories, Kellstrom Aerospace, Interim HealthCare and Quest Diagnostics.

    Mr. Berberian currently serves on the Elon University Board of Trustees and previously chaired the NC State Computer Science Strategic Advisory Board. He holds a bachelor's degree in business administration and information technology from Thomas Edison State College.

    About Privia Health

    Privia Health™ is one of the largest physician enablement companies in the United States with a presence in 15 states and the District of Columbia. Privia builds scaled provider networks with primary-care centric medical groups, risk-bearing entities, a physician-led governance structure, and the Privia Platform comprising an extensive suite of technology and service solutions. Privia collaborates with medical groups, health plans and health systems to optimize 1,200+ physician practices, improve the patient experience for 5.2+ million patients, and reward 4,800+ physicians and advanced practitioners for delivering high-value care.

    Privia's mission is to transform healthcare delivery to achieve better outcomes, lower costs, and improve the health of communities and the well-being of providers. For more information, visit priviahealth.com and connect with us on LinkedIn.

    Safe Harbor Statement

    This release may contain forward-looking statements within the meaning of the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the Company's control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in filings with the Securities and Exchange Commission ("SEC"), including those under "Risk Factors" therein. Should one or more of these risks or uncertainties materialize, or should any of the assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Forward-looking statements speak only as of the date made. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

    Contact:

    Robert Borchert

    SVP, Investor & Corporate Communications

    [email protected]         

    817.783.4841



    Primary Logo

    Get the next $LH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LH
    $PRVA

    CompanyDatePrice TargetRatingAnalyst
    Privia Health Group Inc.
    $PRVA
    1/9/2026$31.00Outperform
    RBC Capital Mkts
    Privia Health Group Inc.
    $PRVA
    11/13/2025$30.00Outperform
    BMO Capital Markets
    Labcorp Holdings Inc.
    $LH
    7/10/2025$260.00Buy → Hold
    HSBC Securities
    Labcorp Holdings Inc.
    $LH
    4/2/2025$276.00Buy
    Redburn Atlantic
    Labcorp Holdings Inc.
    $LH
    3/4/2025$250.00 → $300.00Neutral → Buy
    Citigroup
    Privia Health Group Inc.
    $PRVA
    1/10/2025$25.00Buy
    Needham
    Labcorp Holdings Inc.
    $LH
    1/7/2025$260.00 → $265.00In-line → Outperform
    Evercore ISI
    Privia Health Group Inc.
    $PRVA
    12/16/2024Outperform
    Macquarie
    More analyst ratings

    $LH
    $PRVA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Labcorp to Announce Fourth Quarter Financial Results on February 17, 2026

    BURLINGTON, N.C., Jan. 15, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the fourth quarter of 2025 before the market opens on Tuesday, February 17, 2026. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. The call will be webcast live on the Labcorp Investor Relations website. Partici

    1/15/26 4:15:00 PM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp Declares Quarterly Dividend

    BURLINGTON, N.C., Jan. 14, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on March 12, 2026, to stockholders of record as of the close of business on February 27, 2026. About LabcorpLabcorp (NYSE:LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and c

    1/14/26 6:50:00 AM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp Expands MRD Testing for Breast, Lung and Colon Cancer Recurrence Risk

    Molecular residual disease (MRD) testing detects cancer recurrence months before traditional imagingLabcorp MRD tests now monitor recurrence risk across stage I–III breast cancer, stage I–IIIA non-small cell lung cancer and stage III colon cancerBURLINGTON, N.C., Jan. 13, 2026 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today announced the continued expansion of its molecular residual disease (MRD)i portfolio designed to help clinicians detect cancer recurrence earlier than traditional imaging. The expanded offerings include Labcorp Plasma Detect ID, a whole exome sequence-guided, personalized panel for patients with stage I–III bre

    1/13/26 7:00:00 AM ET
    $LH
    Medical Specialities
    Health Care

    $LH
    $PRVA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Boehler Adam bought $6,006 worth of shares (364 units at $16.50) (SEC Form 4)

    4 - Privia Health Group, Inc. (0001759655) (Issuer)

    6/13/24 4:05:22 PM ET
    $PRVA
    Medical/Nursing Services
    Health Care

    Boehler Adam bought $87,549 worth of shares (5,306 units at $16.50) (SEC Form 4)

    4 - Privia Health Group, Inc. (0001759655) (Issuer)

    5/31/24 4:13:08 PM ET
    $PRVA
    Medical/Nursing Services
    Health Care

    Boehler Adam bought $70,577 worth of shares (4,280 units at $16.49) (SEC Form 4)

    4 - Privia Health Group, Inc. (0001759655) (Issuer)

    5/29/24 4:08:14 PM ET
    $PRVA
    Medical/Nursing Services
    Health Care

    $LH
    $PRVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Meltzer Jonathan C claimed ownership of 2,518 shares (SEC Form 3)

    3 - LABCORP HOLDINGS INC. (0000920148) (Issuer)

    1/12/26 10:04:35 AM ET
    $LH
    Medical Specialities
    Health Care

    New insider Kyle Kathryn W claimed ownership of 3,052 shares (SEC Form 3)

    3 - LABCORP HOLDINGS INC. (0000920148) (Issuer)

    1/12/26 9:56:27 AM ET
    $LH
    Medical Specialities
    Health Care

    New insider Vaughn Bryan T claimed ownership of 5,147 shares (SEC Form 3)

    3 - LABCORP HOLDINGS INC. (0000920148) (Issuer)

    1/12/26 9:50:33 AM ET
    $LH
    Medical Specialities
    Health Care

    $LH
    $PRVA
    SEC Filings

    View All

    $LH
    $PRVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Labcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)

    1/15/26 4:21:51 PM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)

    1/14/26 6:53:13 AM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)

    12/30/25 4:17:08 PM ET
    $LH
    Medical Specialities
    Health Care

    RBC Capital Mkts initiated coverage on Privia Health with a new price target

    RBC Capital Mkts initiated coverage of Privia Health with a rating of Outperform and set a new price target of $31.00

    1/9/26 8:12:05 AM ET
    $PRVA
    Medical/Nursing Services
    Health Care

    BMO Capital Markets initiated coverage on Privia Health with a new price target

    BMO Capital Markets initiated coverage of Privia Health with a rating of Outperform and set a new price target of $30.00

    11/13/25 9:16:05 AM ET
    $PRVA
    Medical/Nursing Services
    Health Care

    Labcorp Holdings Inc. downgraded by HSBC Securities with a new price target

    HSBC Securities downgraded Labcorp Holdings Inc. from Buy to Hold and set a new price target of $260.00

    7/10/25 9:03:30 AM ET
    $LH
    Medical Specialities
    Health Care

    $LH
    $PRVA
    Leadership Updates

    Live Leadership Updates

    View All

    Labcorp Appoints Victor Bulto to Board of Directors

    Bulto, President, U.S. of Novartis, brings global healthcare leadership and growth track record to support Labcorp's long-term strategy BURLINGTON, N.C., Nov. 24, 2025 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today announced the appointment of Victor Bulto, a seasoned pharmaceutical executive and member of Novartis' executive leadership team, to its Board of Directors, effective December 1, 2025. Bulto is an accomplished global executive with 25 years of experience in healthcare, and a proven track record of leadin

    11/24/25 8:30:00 AM ET
    $LH
    Medical Specialities
    Health Care

    Privia Health Expands Value-Based Care Footprint with Acquisition of Accountable Care Organization Business from Evolent Health

    ARLINGTON, Va., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (NASDAQ:PRVA) announced that it signed a definitive agreement to acquire an Accountable Care Organization (ACO) business from Evolent Health, Inc. (NYSE:EVH). The ACO business cares for over 120,000 attributed lives through the Medicare Shared Savings Program (MSSP), as well as various commercial and Medicare Advantage programs. With this transaction, Privia Health will now serve approximately 1.5 million attributed lives in value-based care (VBC) arrangements across commercial, Medicare, Medicare Advantage and Medicaid. Privia Health will pay $100 million in cash at closing and up to an additional $13 million su

    9/23/25 4:10:00 PM ET
    $EVH
    $PRVA
    Other Consumer Services
    Consumer Discretionary
    Medical/Nursing Services
    Health Care

    Privia Health Announces Appointment of Lance V. Berberian to its Board of Directors

    ARLINGTON, Va., July 08, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (NASDAQ:PRVA) announced the appointment of Lance V. Berberian to its Board of Directors, effective July 15, 2025. He has also been named a member of the Audit Committee of the Board. Following the appointment of Mr. Berberian, the Board will comprise 10 directors. "We are excited to welcome Lance to our Board of Directors," said David King, Chairman of the Board, Privia Health Group, Inc. "Lance brings extensive technology strategy and digital transformation experience to the Board, including IT governance, infrastructure management and cybersecurity. We believe his expertise will be invaluable to Privia Health as

    7/8/25 9:00:00 AM ET
    $LH
    $PRVA
    Medical Specialities
    Health Care
    Medical/Nursing Services

    $LH
    $PRVA
    Financials

    Live finance-specific insights

    View All

    Labcorp to Announce Fourth Quarter Financial Results on February 17, 2026

    BURLINGTON, N.C., Jan. 15, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the fourth quarter of 2025 before the market opens on Tuesday, February 17, 2026. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. The call will be webcast live on the Labcorp Investor Relations website. Partici

    1/15/26 4:15:00 PM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp Declares Quarterly Dividend

    BURLINGTON, N.C., Jan. 14, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on March 12, 2026, to stockholders of record as of the close of business on February 27, 2026. About LabcorpLabcorp (NYSE:LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and c

    1/14/26 6:50:00 AM ET
    $LH
    Medical Specialities
    Health Care

    NAMSA Announces Strategic Acquisition of Select Assets of the Early Development Medical Device Testing Business of Labcorp

    TOLEDO, Ohio, Jan. 8, 2026 /PRNewswire/ -- NAMSA, a global leader in medical device testing, clinical research, and regulatory consulting, is pleased to announce it has completed the acquisition of the Early Development medical device testing business of Labcorp (NYSE:LH), a leading provider of innovative and comprehensive laboratory services. This strategic move underscores NAMSA's commitment to advancing innovation and accelerating time-to-market for MedTech manufacturers worldwide. As a result of the acquisition, NAMSA assumes the U.S. portfolio of services of Labcorp's Ear

    1/8/26 8:30:00 AM ET
    $LH
    Medical Specialities
    Health Care

    $LH
    $PRVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Privia Health Group Inc.

    SC 13G/A - Privia Health Group, Inc. (0001759655) (Subject)

    11/14/24 5:20:21 PM ET
    $PRVA
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Privia Health Group Inc.

    SC 13G/A - Privia Health Group, Inc. (0001759655) (Subject)

    11/12/24 10:34:17 AM ET
    $PRVA
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Privia Health Group Inc.

    SC 13G/A - Privia Health Group, Inc. (0001759655) (Subject)

    7/10/24 1:14:41 PM ET
    $PRVA
    Medical/Nursing Services
    Health Care